A Look At Core Scientific (CORZ) Valuation After Q1 Results And Accelerated AI Data Center Expansion

Core Scientific (CORZ) is back in focus after Q1 2026 results showed revenue of US$115.24 million and a loss of US$347.19 million, alongside accelerated AI data center and Muskogee power expansion plans.

See our latest analysis for Core Scientific.

The stock has been volatile around the Q1 2026 loss and large impairment charge. However, a 7 day share price return of 5.49% and 30 day share price return of 21.96% sit alongside a 90 day share price return of 40.51% and a very large 1 year total shareholder return of 123.13%, suggesting momentum has been building as investors react to AI data center expansion plans and fresh institutional interest.

If you are watching how AI infrastructure stories like Core Scientific are trading, it can be helpful to compare it with other potential opportunities using our 42 AI infrastructure stocks.

With revenue growing, fresh AI data center plans and a large impairment driven loss, the share price has already run hard. So are you looking at an undervalued AI infrastructure stock, or has the market already priced in future growth?

Most Popular Narrative: 8.3% Undervalued

Core Scientific's most followed narrative points to a fair value of $26.40, compared with the last close at $24.21, putting the focus firmly on whether AI hosting and power expansion can carry that gap.

Core Scientific secured a major HPC contract with CoreWeave, with a total revenue potential of $8.7 billion over a 12-year term, significantly boosting future revenue compared to their current levels. The company is expanding HPC infrastructure capacity by reallocating resources from Bitcoin mining, adding new sites, and extending existing ones, expecting to drive future revenue growth as data center needs rise.

Read the complete narrative.

Curious what sits behind that fair value gap? The narrative leans heavily on rapid top line growth, a sharp swing in profitability and a richer future earnings multiple. The exact path is baked into detailed revenue curves, margin assumptions and share count changes. Those building a thesis around Core Scientific's AI infrastructure pivot will likely want to see how those moving parts interact in the full narrative.

Result: Fair Value of $26.40 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this narrative leans heavily on executing the CoreWeave contract and successfully shifting capacity from Bitcoin mining to AI hosting. Both of these initiatives carry clear execution risk.

Find out about the key risks to this Core Scientific narrative.

Another View: Rich Sales Multiple Raises the Bar

While the most popular narrative sits on an 8.3% discount to a fair value of $26.40, Core Scientific is trading on a P/S of 21.7x. That is much higher than the US Software industry at 3.5x, peers at 4.6x and a fair ratio of 6x, which points to a high bar for future execution. Does that premium feel comfortable for you as an investor?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed sentiment running through this story, now is the time to look at the full picture yourself and weigh the trade off between risk and opportunity using our 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Core Scientific has caught your attention, do not stop here. Broaden your watchlist and give yourself more options by checking out these focused stock ideas.

• Target potential mispricing by scanning companies that combine quality and value using our 51 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks with higher yields and resilient payouts through our 14 dividend fortresses.
• Reduce portfolio stress by focusing on companies with sturdier finances using our solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com